Card image cap
Trinity study finds new therapeutic target for asthma

A molecule made by our own bodies, called Itaconate, can suppress key events that promote asthma by targeting an important immune protein called JAK1, reveals the latest research by a team of scientists at School of Biochemistry and Immunology at Trinity Biomedical Sciences Institute (TBSI).  The research project, led by Dr Luke O’Neill, a professor of Biochemistry, found that blocking JAK1 has shown remarkable efficacy in lab-based models of severe asthma. The findings, published in Cell, indicated the possibility of medicines based on Itaconate having potential as a new therapeutic approach to treat asthma.

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.

Supported by Koye Pharmaceuticals

Submit a Comment